Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel: NK/T-cell Lymphoma

Explore the latest updates and expert interviews

The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Welcome to The NK/T-Cell Lymphoma Channel

VJHemOnc brings you all of the latest news in the field of NK/T-cell lymphoma, as presented by top experts. The NK/T-Cell Lymphoma Channel covers all of the state-of-the-art updates in NK/T-cell lymphoma from international congresses, including video interviews on presentations and abstracts, podcasts, and roundtable discussions with key opinion leaders.

Explore The NK/T-Cell Lymphoma Channel to learn about the latest advances in the field, including the use of novel therapies and combination regimens, and research identifying prognostic biomarkers.

The EBMT consensus guidelines for alloSCT in T-cell lymphoma 5:03
The EBMT consensus guidelines for alloSCT in T-cell lymphoma
Gandhi Damaj • 31 Mar 2025
DR-01, an anti-CD94 monoclonal antibody, in the treatment of ultra-rare cytotoxic T-cell lymphomas 1:38
DR-01, an anti-CD94 monoclonal antibody, in the treatment of ultra-rare cytotoxic T-cell lymphomas
Swaminathan Iyer • 9 Dec 2024
Updates in T-cell leukemia/lymphoma
Francine Foss et al. • 9 Oct 2024
The risk of T-cell malignancies associated with CAR T-cell therapy 2:20
The risk of T-cell malignancies associated with CAR T-cell therapy
Yi Lin • 9 Dec 2023
DISTINKT trial analysis: efficacy and safety of IMC-001 for R/R ENKTL 1:11
DISTINKT trial analysis: efficacy and safety of IMC-001 for R/R ENKTL
Won-Seog Kim • 16 Jun 2023
Promising advances in the field of PTCL: druggable mutations, brentuximab vedotin & L-asparaginase 2:15
Promising advances in the field of PTCL: druggable mutations, brentuximab vedotin & L-asparaginase
Christian Gisselbrecht • 25 Apr 2023
IMC-001: preliminary results of novel PD-L1 inhibitor for R/R extranodal NK/T cell lymphoma 2:04
IMC-001: preliminary results of novel PD-L1 inhibitor for R/R extranodal NK/T cell lymphoma
Won-Seog Kim • 24 Nov 2022
Approaching NK/T-cell lymphoma 0:42
Approaching NK/T-cell lymphoma
Won-Seog Kim • 11 Jun 2022
Results of Phase II study of tislelizumab in R/R NK/T-cell neoplasms 1:15
Results of Phase II study of tislelizumab in R/R NK/T-cell neoplasms
Emmanuel Bachy • 11 Jun 2022
Advances in treating T-cell lymphoma 3:56
Advances in treating T-cell lymphoma
Franco Cavalli • 24 Jun 2021
Advances in extranodal natural killer/T-cell lymphoma 8:54
Advances in extranodal natural killer/T-cell lymphoma
Qing-qing Cai • 24 Jun 2021
EGR1 as a prognostic biomarker in ENKTL 1:07
EGR1 as a prognostic biomarker in ENKTL
Won-Seog Kim • 21 Jun 2021
Novel issues in the combined modality treatment of lymphomas 2:55
Novel issues in the combined modality treatment of lymphomas
Lena Specht • 14 Jun 2017
An overview on NK/T-cell lymphoma treatment 1:58
An overview on NK/T-cell lymphoma treatment
Won-Seog Kim • 14 Jun 2017

The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Diamond Supporter

AstraZeneca

Gold Supporter

BMS Johnson & Johnson

Silver Supporter

Takeda

Bronze Supporter

Galapagos

If you are interested in becoming a supporter of The Lymphoma Channel, please contact us.

The content of VJHemOnc is intended for healthcare professionals